## Supplementary Table 3. Sensitivity analysis with network meta-analysis results for primary and secondary prophylaxis of variceal bleeding

|  |
| --- |
| **Bleeding (primary + secondary prophylaxis):** 28 studies; 2,823 participants  |
| Carvedilol 1.29 (0.22, 6.30)  |   Nadolol\*  |
| 0.60 (0.12, 2.29)  | 0.47 (0.17, 1.16) Propranolol  |
| 0.32 (0.06, 1.20)  | **0.25 (0.10, 0.56)** **0.53 (0.36, 0.77)** Placebo  |

**Bleeding (primary prophylaxis):** 11 studies; 1,593 participants

 Carvedilol

 2.98 (0.14, 50.77) Nadolol

 0.68 (0.05, 5.04) 0.23 (0.02, 1.74) Propranolol

 0.42 (0.04, 2.94) **0.14 (0.02, 0.91)** 0.62 (0.27, 1.61) Placebo

**Bleeding (secondary prophylaxis):** 17 studies; 1,230 participants

|  |  |  |  |
| --- | --- | --- | --- |
| Carvedilol 0.37 (0.01, 6.47)  | Nadolol\*  |   |   |
| 0.24 (0.01, 2.99)  | 0.64 (0.18, 2.22)  | Propranolol  |   |
| 0.11 (0.00, 1.54)  | **0.30 (0.09, 0.96)**  | **0.47 (0.29, 0.78)**  | Placebo  |

Data are presented as pooled relative risk (95% credible interval). \*One study using the combination of nadolol and isosorbide mononitrate was excluded. Bold text indicates statistically significant value.